Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Next Pharma’s Nexrutine meets trial goals in pain alleviation
Out of the 401 participants, 369 (92%) reported that Nexrutine provided pain relief and 373 (93%) reported improvement in their overall condition. In total, 361 (90%) reported Nexrutine
Out of the 401 participants, 369 (92%) reported that Nexrutine provided pain relief and 373 (93%) reported improvement in their overall condition. In total, 361 (90%) reported Nexrutine
BioTech intends to add more assets and increased revenue for the company in 2008 to bring more value to the stock. BioBody is an eight-year-old Texas company that
This method patent covers the use of multispectral imaging combined with spectral unmixing to greatly increase the signal-to-noise level of fluorophores in a living mammal. The unmixing of
Niacin is a treatment is used to increase high density lipoprotein (HDL) and modestly decrease triglyceride levels in dyslipidemia or cholesterol management. Ultra-pure ethyl EPA prescribed in Japan
In addition to seeking guidance on the P2V diagnostic test, the pre- investigational device exemption (IDE) application will also include an investigational plan overview for the tumor grading
The circulatory system devices advisory panel to the FDA voted to recommend the Xience V stent system for approval with conditions related to post-marketing study requirements and language
Lilly’s $1.6 million contribution will finance programs between 2008 and 2011. In 2008 alone, the International Federation will expand its support to 10 additional MDR-TB programs in Kazakhstan,
This is the first clinical trial of a compound in this collaboration to discover novel therapies targeted against LXR, a nuclear hormone receptor implicated in a variety of
Existing investors Ampersand Ventures, Adams Street Partners and Tang Capital Management participated in the financing. Ronald Berg, president and CEO of RadPharm, said: “This financing marks another key
The procedure was performed as part of NeoVista’s Cabernet trial, which seeks to enroll a total of 450 patients (300 in the radiation treatment arm) in approximately 40